1. Home
  2. PLXS vs ARQT Comparison

PLXS vs ARQT Comparison

Compare PLXS & ARQT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

PLXS

Plexus Corp.

HOLD

Current Price

$153.07

Market Cap

4.0B

Sector

Technology

ML Signal

HOLD

Logo Arcutis Biotherapeutics Inc.

ARQT

Arcutis Biotherapeutics Inc.

HOLD

Current Price

$28.33

Market Cap

3.3B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
PLXS
ARQT
Founded
1979
2016
Country
United States
United States
Employees
N/A
N/A
Industry
Electrical Products
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
4.0B
3.3B
IPO Year
1986
2020

Fundamental Metrics

Financial Performance
Metric
PLXS
ARQT
Price
$153.07
$28.33
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
3
7
Target Price
$160.00
$24.83
AVG Volume (30 Days)
220.3K
2.0M
Earning Date
01-21-2026
10-28-2025
Dividend Yield
N/A
N/A
EPS Growth
56.11
N/A
EPS
6.26
N/A
Revenue
$4,032,966,000.00
$317,929,000.00
Revenue This Year
$10.99
$85.51
Revenue Next Year
$7.02
$30.74
P/E Ratio
$24.49
N/A
Revenue Growth
1.82
129.21
52 Week Low
$103.43
$11.13
52 Week High
$172.89
$31.77

Technical Indicators

Market Signals
Indicator
PLXS
ARQT
Relative Strength Index (RSI) 53.86 51.12
Support Level $147.43 $27.55
Resistance Level $166.91 $28.90
Average True Range (ATR) 6.10 1.15
MACD -0.31 -0.55
Stochastic Oscillator 42.46 18.58

Price Performance

Historical Comparison
PLXS
ARQT

About PLXS Plexus Corp.

Plexus Corp designs, manufactures, and services complex products in demanding regulatory environments, supporting life-saving medical devices, mission-critical aerospace and defense products, industrial automation systems, and semiconductor capital equipment. Its integrated lifecycle solutions span design and development, supply chain solutions, new product introduction, manufacturing, and sustaining services for market and disruptive companies in the Aerospace/Defense, Healthcare/Life Sciences, and Industrial sectors. The Company operates through three reportable segments: AMER, APAC, and EMEA, with the majority of revenue from the APAC segment.

About ARQT Arcutis Biotherapeutics Inc.

Arcutis Biotherapeutics Inc is a medical dermatology company. It is developing treatments for patients with immune-mediated dermatological diseases and conditions. It is leveraging recent advances in immunology and inflammation to develop differentiated therapies against biologically validated targets to solve persistent treatment challenges in serious diseases of the skin. The company's product candidate ZORYVE roflumilast cream, has completed pivotal Phase 3 clinical trials in plaque psoriasis, demonstrating symptomatic improvement and favorable tolerability in this population.

Share on Social Networks: